[Cost-efficacy of new antiviral treatments for chronic hepatitis C].
作者信息
Lens Sabela, Bonacci Martín
机构信息
Servicio de Hepatología, Hospital Clínic Barcelona, IDIBAPS, CIBERehd.
Servicio de Hepatología, Hospital Clínic Barcelona, IDIBAPS, CIBERehd.
出版信息
Aten Primaria. 2015 Oct;47(8):479-81. doi: 10.1016/j.aprim.2015.06.004.
Abstract
摘要
相似文献
1
[Cost-efficacy of new antiviral treatments for chronic hepatitis C].
Aten Primaria. 2015 Oct;47(8):479-81. doi: 10.1016/j.aprim.2015.06.004.
2
[Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice].[特拉匹韦和博赛匹韦用于慢性丙型肝炎真实世界临床实践的成本效益及安全性]
Gastroenterol Hepatol. 2015 Dec;38(10):575-82. doi: 10.1016/j.gastrohep.2015.07.002. Epub 2015 Aug 28.
3
A cure for the high cost of hepatitis C virus treatment.丙型肝炎病毒治疗高昂费用的解决办法。
Ann Intern Med. 2015 May 5;162(9):660-1. doi: 10.7326/M15-0674.
4
Interferon-alpha for chronic hepatitis C: reducing the uncertainties.
Ann Intern Med. 1997 Nov 15;127(10):918-20. doi: 10.7326/0003-4819-127-10-199711150-00011.
5
Sticker shock and the price of new therapies for hepatitis C: is it worth it?丙肝新疗法带来的价格震惊：这值得吗？
Hepatology. 2014 Apr;59(4):1246-9. doi: 10.1002/hep.27039. Epub 2014 Mar 1.
6
'HepConomics': cost-effective, indeed, but how can we pay for it?
J Viral Hepat. 2015 Aug;22(8):682. doi: 10.1111/jvh.12396. Epub 2015 Feb 27.
7
Economics of chronic hepatitis B and hepatitis C.慢性乙型肝炎和丙型肝炎的经济学
J Hepatol. 2007 Oct;47(4):608-17. doi: 10.1016/j.jhep.2007.07.016. Epub 2007 Jul 30.
8
Why We Should Be Willing to Pay for Hepatitis C Treatment.我们为何愿意为丙型肝炎治疗付费。
Clin Gastroenterol Hepatol. 2015 Oct;13(10):1711-3. doi: 10.1016/j.cgh.2015.06.005. Epub 2015 Jun 16.
9
Special report: cost-effectiveness studies of new hepatitis C treatments.特别报道：新型丙型肝炎治疗方法的成本效益研究
Technol Eval Cent Assess Program Exec Summ. 2015 Jan;29(10):1-3.
10
Combination therapy in naive patients with chronic hepatitis C: more value for the money.初治慢性丙型肝炎患者的联合治疗：性价比更高。
J Hepatol. 2000 Oct;33(4):664-6. doi: 10.1034/j.1600-0641.2000.033004664.x.
本文引用的文献
1
EASL Recommendations on Treatment of Hepatitis C 2015.2015年欧洲肝脏研究学会丙型肝炎治疗指南
J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21.
2
Clinical trial watch: reports from the AASLD Liver Meeting®, Boston, November 2014.临床实验观察：AASLD 肝脏会议报告，波士顿，2014 年 11 月。
J Hepatol. 2015 May;62(5):1196-203. doi: 10.1016/j.jhep.2015.01.028. Epub 2015 Jan 31.
3
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus.索磷布韦为基础的方案治疗丙型肝炎病毒后 4、12 和 24 周时持续病毒学应答的一致性。
Hepatology. 2015 Jan;61(1):41-5. doi: 10.1002/hep.27366. Epub 2014 Nov 24.
4
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.目前和未来的丙型肝炎病毒 (HCV) 感染的疾病负担与今天的治疗模式。
J Viral Hepat. 2014 May;21 Suppl 1:34-59. doi: 10.1111/jvh.12248.
5
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.telaprevir 或 boceprevir 治疗慢性丙型肝炎 1 型感染合并肝硬化患者的疗效。
Gastroenterology. 2014 Jul;147(1):132-142.e4. doi: 10.1053/j.gastro.2014.03.051. Epub 2014 Apr 3.
6
[Future prospects for hepatitis C treatment: without interferon and ribavirin?].[丙型肝炎治疗的未来前景：无需干扰素和利巴韦林？]
Gastroenterol Hepatol. 2014 May;37(5):311-21. doi: 10.1016/j.gastrohep.2014.01.002. Epub 2014 Mar 27.
7
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.慢性丙型肝炎合并晚期肝纤维化患者持续病毒学应答与全因死亡率的关系。
JAMA. 2012 Dec 26;308(24):2584-93. doi: 10.1001/jama.2012.144878.
8
The natural history of recurrent hepatitis C and what influences this.复发性丙型肝炎的自然病史及其影响因素。
Liver Transpl. 2008 Oct;14 Suppl 2:S36-44. doi: 10.1002/lt.21646.
9
[Hepatitis C in Spain].[西班牙的丙型肝炎]
Med Clin (Barc). 2006 Jun 17;127(3):113-7. doi: 10.1157/13090276.
10
Treatment of patients with hepatitis C and cirrhosis.
Hepatology. 2002 Nov;36(5 Suppl 1):S185-94. doi: 10.1053/jhep.2002.36812.
Zotero 插件